Filing Details

Accession Number:
0001213900-22-024052
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-05-04 20:01:39
Reporting Period:
2022-05-02
Accepted Time:
2022-05-04 20:01:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1819790 Tarsus Pharmaceuticals Inc. TARS () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1750117 Vivo Capital Fund Ix, L.p. C/O Vivo Capital Llc
192 Lytton Avenue
Palo Alto, CA 94301
No No Yes No
1750698 Vivo Capital Ix, Llc C/O Vivo Capital Llc
192 Lytton Avenue
Palo Alto, CA 94301
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-05-02 41,800 $15.19 2,945,531 No 4 S Indirect See Footnote
Common Stock Disposition 2022-05-03 451,418 $13.25 2,494,113 No 4 S Indirect See Footnote
Common Stock Disposition 2022-05-04 19,738 $12.67 2,474,375 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Footnotes
  1. The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.75 to $15.92, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
  2. The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.05 to $13.89, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
  3. The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $ 12.25 to $13.00 inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
  4. The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.